NASDAQ: PRLDPrelude Therapeutics Inc Stock
$0.88+0.04 (+4.76%)
Updated Jun 24, 2025
PRLD Price
$0.88
Fair Value Price
$0.69
Market Cap
$49.46M
52 Week Low
$0.61
52 Week High
$6.80
P/E
-0.52x
P/B
0.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$127.83M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.37
Operating Cash Flow
-$105M
Beta
1.44
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRLD Overview
Prelude Therapeutics Incorporated develops novel precision cancer medicines for underserved patients. PRT543 targets select solid tumors and myeloid malignancies; PRT811 targets solid tumors, including glioblastoma multiforme. Prelude Therapeutics was founded in 2016 and is headquartered in Wilmington, DE.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRLD's potential to beat the market
- PRLD doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PRLD
RankedUnranked of 466
RankedUnranked of 466
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.05 | A | |
| $45.72 | A | |
| $22.07 | A |
Be the first to know about important PRLD news, forecast changes, insider trades & much more!
PRLD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRLD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRLD ($0.88) is overvalued by 26.4% relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PRLD ($0.88) is not significantly undervalued (26.4%) relative to our estimate of its Fair Value price of $0.69 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PRLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PRLD due diligence checks available for Premium users.
Valuation
PRLD fair value
Fair Value of PRLD stock based on Discounted Cash Flow (DCF)
Price
$0.88
Fair Value
$0.69
Overvalued by
26.98%
PRLD ($0.88) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PRLD ($0.88) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PRLD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRLD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.52x
Industry
-122.73x
Market
32.13x
PRLD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.48x
Industry
4.52x
PRLD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRLD's financial health
Profit margin
Revenue
$0.0
Net Income
-$32.1M
Profit Margin
0%
PRLD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$141.3M
Liabilities
$38.1M
Debt to equity
0.37
PRLD's short-term assets ($102.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRLD's short-term assets ($102.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRLD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.2M
Investing
$62.2M
Financing
-$160.0k
PRLD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRLD vs Biotech Stocks
Prelude Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.